Follow-up of COVID-19 Vaccine Response in Strasbourg University Hospitals

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

800 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-04-30

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Vaccination remains the main promising measure to fight against the COVID-19 pandemic. The presumed efficacy of the vaccines is quite remarkable since it varies between 62 and 95%. There is increasing evidence that sex-specific effects may lead to different outcomes of vaccine safety and efficacy. However, sex-disaggregated data after COVID-19 vaccine are lacking. The first purpose of the study is to determine antibody titers against SARS-CoV-2 spike after COVID-19 vaccination. The secondary purpose is to identify predictor factors of immune response including age, gender and biological factors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Monitoring of the Post-vaccination Immune Response to COVID-19 Among Hospital Staff

NCT04896788

Hospital Staff Vaccined Againt COVID-19

UNKNOWN NA

CoViD-19 Patient in Reims University Hospital in March to April 2020

NCT04553575

Coronavirus Infections

COMPLETED

Prospective Clinical and Virological Analysis of Healthcare Workers Diagnosed Positive for Covid-19.

NCT04858581

Covid19

UNKNOWN NA

RT-PCR SARS-CoV-2 at 1 Month of COVID-19 Infection in the Geriatric Population

NCT04427358

Covid-19

COMPLETED

Description of Immunologic, Enzymatic and Metabolic Biomarkers Associated to the Severity of COVID-19 (SARS-CoV-2) and Its Resolution

NCT04664023

Covid19

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19 Vaccines

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- Any person, male or female, over 18 years of age who underwent vaccination and

* anti-SARS-CoV-2 serological test after vaccination
* having already given their consent for their biological resources to be:

* stored in a biocollection of the Microbiology Technical Platform (PTM) having received an approval from the CPP Est-IV and declared to the Ministry of Education and Research under reference No. DC2009-1002;
* subsequently reused, as well as the anonymized associated data, for research purposes

Exclusion Criteria

* Inability to give clear information (person in an emergency, difficulty understanding the subject, etc.)
* Person under safeguard of justice
* Person under guardianship or curatorship-

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No